Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917778 | 0.88 | BRD4 (0.38) | JAK3LMNAPTK2JAK1EPHB4 | |
| SCHEMBL4916910 | 0.85 | LRRK2 (0.50) | JAK3PTK2JAK1EPHB4MET | |
| SCHEMBL4923439 | 0.83 | PDE5A (0.48) | JAK3PTK2JAK1EPHB4MET | |
| SCHEMBL4916374 | 0.82 | PDE5A (0.50) | LMNATDP1PTK2NPSR1 | |
| SCHEMBL4909075 | 0.82 | PDE5A (0.39) | JAK3PTK2JAK1EPHB4MET | |
| SCHEMBL4914810 | 0.81 | PTK2 (0.41) | JAK3PTK2JAK1EPHB4MET | |
| SCHEMBL4920898 | 0.81 | PDE5A (0.45) | JAK3PTK2JAK1EPHB4BRD4 | |
| SCHEMBL4914819 | 0.81 | PDE5A (0.44) | JAK3LMNAPTK2JAK1BRD4 | |
| SCHEMBL4914617 | 0.80 | TAAR1 (0.40) | JAK3PTK2JAK1EPHB4MET | |
| SCHEMBL4696226 | 0.80 | PTK2 (0.45) | JAK3LMNAPTK2JAK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | JAK3 5/4885LMNA 4151/4885TDP1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.